Pharvaris NV is a clinical-stage biopharmaceutical company focused on the development of novel therapies for the treatment of rare diseases. The company was founded in 2016 and is headquartered in Leiden, the Netherlands. Pharvaris specializes in the discovery and development of small molecule drugs that target the kallikrein-kinin system, a biological pathway involved in various inflammatory and edematous disorders.
Pharvaris' lead product candidate is known as PHA121, a selective bradykinin B2 receptor antagonist. The company is developing PHA121 for the treatment of hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of swelling in various parts of the body. PHA121 has demonstrated promising results in clinical trials and has the potential to provide patients with a convenient and effective treatment option.
As a clinical-stage company, Pharvaris is primarily focused on advancing its product candidates through clinical development. The company conducts rigorous clinical trials to assess the safety and efficacy of its therapies and seeks regulatory approval for commercialization. Pharvaris collaborates with leading experts, clinical centers, and research organizations to accelerate the development of its pipeline and bring innovative therapies to patients in need.
The work of Pharvaris is driven by a strong commitment to addressing unmet medical needs in rare diseases. The company strives to provide improved treatment options for patients suffering from conditions such as hereditary angioedema, where limited treatment options are currently available. Pharvaris' focus on the kallikrein-kinin system and its dedication to developing targeted therapies distinguish it as a leader in the field of rare diseases and position it for potential success in the pharmaceutical industry.